scorecardresearch
Add as a preferred source on Google
Friday, December 19, 2025
TopicSerum Institute of India

Topic: Serum Institute of India

Serum Institute of India gets govt nod to export 5 crore doses of Covovax to Indonesia

Covovax has been developed by Novavax and is being manufactured by the Pune-based SII, but is not cleared for emergency use in India.

Novavax’s Covid vaccine, made by Serum Institute of India, gets emergency use nod in Indonesia

Serum Institute of India, world's largest vaccine manufacturer, will market the nanoparticle protein-based vaccine in Indonesia under the brand name Covovax.

Vaccine makers upset over ‘differential pricing’ for ZyCov-D, and lack of clarity on exports

ZyCov-D has reportedly been priced by the company at Rs 1,900 for three doses while the others cost between Rs 205-215 per dose.

Biocon partners SII to make vaccine, drug manufacturing accessible to developing nations

Under the deal, Biocon Biologics Ltd (BBL) will offer approximately 15% stake to Serum Institute Life Sciences at a post-money valuation of about Rs 35,000 crore.

1 cr/day target achieved, Modi govt looks to administer 100 cr Covid vaccines in next 3 months

If projections of all four vaccine companies in India — SII, Zydus Cadila, Bharat Biotech and Biological E — are met, India is likely to acquire 100 crore more doses between October and December 2021.

Centre places order with Serum Institute of India for 66 crore Covishield doses

SII has enhanced the manufacturing capacity of Covishield to more than 20 crore doses per month, and the latest consignment ordered by Centre is to be supplied by December.

At 16.4 cr doses, SII’s increased Covishield output helps India cross Aug vaccination target

Modi govt, which projected 15 crore doses would be available in August, managed to achieve its 1 crore-doses-a-day plan last week. Meanwhile, Covaxin production lags.

Will supply 20 crore doses of Covishield in September, SII notifies Modi govt

In a production plan submitted to the Centre in May, SII’s director communicated that the production of Covishield would be ramped up to 10 crore each in August, September, said sources.

Serum Institute writes to Health Minister Mansukh Mandaviya to reform drug regulatory system

SII also sought permission to use the remaining quantities of batches of Covid and non-Covid vaccines for commercial purposes which have been used in the clinical trials.

SII to begin manufacturing Sputnik V in India by September, targets 300 million doses a year

Pune-based vaccine manufacturer SII has already received cell and vector samples for the production of Sputnik V from Russia's Gamaleya Center, the developer of the vaccine.

On Camera

Why India fell off the global middle-class map

A stunted middle class may be a direct result of extreme inequality. Folks at the top don’t see teeming masses as a meaningful market, except for utilities, soap, short videos, and personal loans.

India’s financial reforms target a wave of foreign money

Up to 100% foreign ownership of insurance firms, and overhauled rules for banks, pension funds and capital markets aim to shift savings from idle assets toward equities, bonds and long-term investments.

Israel has ‘realised who its real friend is’, eyes defence expansion in India amid arms curbs by others

It is argued that India-Israel ties are moving from buyer–seller dynamic to one focused on joint development & manufacturing partnership, a shift 'more durable' than traditional arms sales.

India’s top airline just handed sarkar the keys. That’s IndiGo’s real ‘crime’

Don’t blame misfortune. This is colossal incompetence and insensitivity. So bad, heads would have rolled even in the old PSU-era Indian Airlines and Air India.